Ochratoxin A: Developmental and reproductive toxicity—An overview
…, A Pfohl‐Leszkowicz, E Novotna - Birth Defects Research …, 2013 - Wiley Online Library
Ochratoxin A (OTA) is nephrotoxic, hepatotoxic, reprotoxic, embryotoxic, teratogenic,
neurotoxic, immunotoxic, and carcinogenic for laboratory and farm animals. Male and female …
neurotoxic, immunotoxic, and carcinogenic for laboratory and farm animals. Male and female …
Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3
J Hofman, B Malcekova, A Skarka, E Novotna… - Toxicology and applied …, 2014 - Elsevier
Pharmacokinetic drug resistance is a serious obstacle that emerges during cancer
chemotherapy. In this study, we investigated the possible role of aldo-keto reductase 1C3 (AKR1C3) …
chemotherapy. In this study, we investigated the possible role of aldo-keto reductase 1C3 (AKR1C3) …
Toxicity of the mycotoxin ochratoxin A in the light of recent data
F Malir, V Ostry, E Novotna - Toxin Reviews, 2013 - Taylor & Francis
Ochratoxin A (OTA) is a ubiquitous, naturally occurring chlorophenolic mycotoxin produced
in contaminated food and feed by fungi of genera Penicillium and Aspergillus. OTA is a …
in contaminated food and feed by fungi of genera Penicillium and Aspergillus. OTA is a …
Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo
Y Budagaga, Z Sabet, Y Zhang, E Novotná… - Biochemical …, 2023 - Elsevier
ATP-binding cassette (ABC) drug efflux transporters and drug metabolizing enzymes play
crucial roles in pharmacokinetic drug-drug interactions and multidrug tumor resistance (MDR). …
crucial roles in pharmacokinetic drug-drug interactions and multidrug tumor resistance (MDR). …
Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase
M Krátký, J Vinšová, E Novotná, J Mandíková, V Wsól… - Tuberculosis, 2012 - Elsevier
The global burden of tuberculosis, its health and socio-economic impacts, the presence of
drug-resistant forms and a potential threat of latent tuberculosis should serve as a strong …
drug-resistant forms and a potential threat of latent tuberculosis should serve as a strong …
Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients
S Bandur, J Petrasek, P Hribova, E Novotna… - …, 2008 - journals.lww.com
Background. Bioavailability of tacrolimus (Tac) and cyclosporine is determined by cytochrome
P450IIIA and by P-glycoprotein encoded by the CYP3A4/CYP3A5 and ABCB1 genes. …
P450IIIA and by P-glycoprotein encoded by the CYP3A4/CYP3A5 and ABCB1 genes. …
[HTML][HTML] Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in …
…, Y Budagaga, Y Zhang, E Novotná… - International Journal of …, 2022 - mdpi.com
Talazoparib (Talzenna) is a novel poly (adenosine diphosphate-ribose) polymerase (PARP)
inhibitor that is clinically used for the therapy of breast cancer. Furthermore, the drug has …
inhibitor that is clinically used for the therapy of breast cancer. Furthermore, the drug has …
Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity …
D Vagiannis, Y Zhang, Y Budagaga, E Novotna… - Toxicology and Applied …, 2022 - Elsevier
Alisertib (MLN8237), a novel Aurora A kinase inhibitor, is currently being clinically tested in
late-phase trials for the therapy of various malignancies. In the present work, we describe …
late-phase trials for the therapy of various malignancies. In the present work, we describe …
[HTML][HTML] Bruton's tyrosine kinase inhibitor zanubrutinib effectively modulates cancer resistance by inhibiting anthracycline metabolism and efflux
…, L Laštovičková, L Havlíčková, I Špringrová, E Novotná… - Pharmaceutics, 2022 - mdpi.com
Zanubrutinib (ZAN) is a Bruton’s tyrosine kinase inhibitor recently approved for the treatment
of some non-Hodgkin lymphomas. In clinical trials, ZAN is often combined with standard …
of some non-Hodgkin lymphomas. In clinical trials, ZAN is often combined with standard …
Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile
E Novotná, N Büküm, J Hofman, M Flaxová… - Archives of …, 2018 - Springer
Dinaciclib is a multi-specific cyclin-dependent kinase (CDK) inhibitor with significant preclinical
and clinical activity. It inhibits CDK1, CDK2, CDK5, CDK9 and CDK12 in the nanomolar …
and clinical activity. It inhibits CDK1, CDK2, CDK5, CDK9 and CDK12 in the nanomolar …